Diagnosing Dependence Between Visits And Outcomes

Why Diagnose Visit–Outcome Dependence?

When patients are measured only at clinic visits, the observed biomarker record reflects both the underlying clinical course and the timing of measurement. If visits become more frequent when a biomarker worsens, or as a clinical event approaches, then measurements collected at visits may overrepresent those periods. A pattern like this matters for joint analyses: a model that treats observation times as unrelated to outcomes may not describe the data-generating process adequately.

A diagnostic is not a proof of the mechanism that generated the visits. High visit frequency near an event may arise because symptoms or biomarker changes prompted care, but it may also reflect a planned monitoring schedule, treatment changes, or unrecorded clinical circumstances. The aim here is to identify, describe, and qualify patterns that are consistent with outcome-dependent observation.

The phrase “after accounting for” is important. A visit intensity that rises during a treatment phase could be associated with outcomes because treatment was initiated in response to deterioration, because the treatment protocol schedules more visits, or both. A useful diagnostic therefore asks not only whether visits and outcomes vary together, but also whether the pattern remains plausible after considering the protocol, eligibility for follow-up, and clinical context.

What to Examine

Three complementary views are especially useful. First, compare visit rates across clinically meaningful outcome-history groups. Second, check whether biomarker history precedes and predicts later visits, rather than merely being measured at the visit itself. Third, inspect visit activity relative to clinical events, using time at risk and a clearly defined reference period.

For a rate comparison, the denominator should be eligible person-time in each group. For example, a group with twice as many visits but three times as much follow-up does not have a higher visit rate. A basic rate is the visit count divided by the time during which a visit could have occurred. If event occurrence ends follow-up, time after the event must not be counted as time at risk for a pre-event visit.

Biomarker summaries need temporal ordering. A biomarker value measured during a visit cannot, by itself, show that the value triggered that same visit. Instead, define a biomarker history using information available before a later visit window begins. Possible summaries include the most recent available value, a recent change, or a prespecified category such as above versus below a clinical threshold. The choice should be clinically interpretable and set without searching repeatedly for a pattern that looks strongest.

For events, compare visits during a prespecified interval before the event with visits in appropriate reference periods. The event itself terminates the period in which a pre-event visit can occur. A rise in visit activity before the event can be consistent with worsening health prompting contact, but it does not show that future event status caused earlier visits. An evolving clinical state may drive both.

Temporal Checks and a Useful Justification

A practical way to strengthen a diagnostic is to start with information available before the period in which visits are counted. For example, among eligible patients, compare the chance of a visit in the next seven days after a high biomarker value with the chance after a low value. This makes the time order explicit. It does not eliminate confounding: a clinician’s concern may affect both the measurement and the decision to schedule follow-up.

The connection between visit frequency and the distribution of measured values can be made precise. Consider a short period in which \(Y(t)\) is the biomarker and \(\lambda^V(t)\) is the visit intensity. If times with larger intensity are more likely to be sampled at a visit, then the mean biomarker value among visits is intensity-weighted. In a setting where the quantities can be pooled over comparable eligible person-time:

For the second equality, expand the numerator as \(E\{Y\lambda^V\}=E(Y)E(\lambda^V)+\operatorname{Cov}(Y,\lambda^V)\), then divide by \(E(\lambda^V)\), assumed positive. If high biomarker values coincide with higher visit intensity, the covariance is positive and the mean measured at visits exceeds the time-weighted mean. This is a justification for taking visit timing seriously, not a claim that every observed association has this cause. The calculation presumes comparable eligible time and a meaningful intensity-weighted sampling interpretation; changes in patient mix or follow-up can invalidate a naive pooled comparison.

Clinical Events, Alternatives, and Failure Modes

Several alternatives help interpret such signals. A protocol-based account predicts visits at planned times, perhaps with more frequent monitoring after treatment changes; comparing actual visits with the schedule can reveal this structure. A purely descriptive rate comparison identifies where visit activity differs but may leave case mix and confounding uncontrolled. An adjusted visit-intensity analysis can condition on measured history and covariates, but its interpretation depends on the adequacy of the model and the variables recorded. Clinical documentation of unscheduled contacts or visit reasons can add useful context, although recorded reasons may be incomplete.

The earlier material on inverse-intensity weighting and conditions for ignoring the visit process addresses how visit mechanisms affect analysis. This diagnostic step is more modest: it asks whether the observed data and context raise a credible concern that the process warrants attention. It does not replace a specified visit-process model, and raw rates do not determine which model should be used.

Common failure modes include the following:

• Comparing counts without exposure time. More visits may simply reflect longer follow-up. Use eligible person-time and state how it was defined.
• Using a biomarker measured at a visit to explain that same visit. This reverses or obscures the time order. Use history available before the visit window.
• Ignoring planned schedules. Protocol visits can create apparent outcome-related patterns if high-risk patients have more intensive planned monitoring.
• Using future event status carelessly. Event patients may differ from non-event patients in follow-up and clinical severity. Define comparable risk periods and do not count time after a terminal event as pre-event risk time.
• Treating repeated periods as independent. Several periods from one patient are correlated. Simple standard errors may be too small unless the analysis accounts for that structure.
• Equating evidence with proof. An association can be consistent with outcome-dependent observation without identifying the trigger or ruling out confounding.

The diagnostic can also fail because the relevant trigger was never recorded, because visit dates are imprecise, or because patients obtained care outside the observed system. A flat pattern in the available data therefore does not prove that observation is noninformative. Conversely, a visible pattern should be checked against the data-collection process: a change in visit coding or follow-up rules can mimic a change in clinical behavior.